Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer

NCT04685070 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer Stage III

Interventions

DRUG: HS-10296 (Almonertinib)

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China